tbuckley/cabot-search huggingface dataset:
Beyond single-use: a systematic review of environmental, economic, and clinical impacts of endoscopic surgical instrumentation
Authors: Myrthe M.M. Eussen, Martine Moossdorff, Lianne M. Wellens, Philip R. de Reuver, Tim Stobernack, Leon Bijlmakers, Merel L. Kimman, Nicole D. Bouvy
Journal: International Journal of Surgery (2024)

Background: The evolution of endoscopic surgery has introduced a multitude of instruments, available in both disposable and reusable variants, influencing practices across various surgical specialties. Instrument selection is complex, considering individual preferences and institutional factors such as costs, instrument performance, and factors related to cleaning and sterilization. Notably, environmental sustainability has gained prominence due to the threat of climate change. This review assessed the existing literature to facilitate evidence-informed decision-making, encompassing clinical and economic efficacy, environmental friendliness, and other important criteria. Materials and Methods: Following PRISMA guidelines, searches were conducted in Pubmed, Embase, Web of Science, and The Cochrane Library for studies comparing the environmental impact, costs, instrument performance, and contamination risk of disposable versus reusable instruments or new versus reprocessed disposables in endoscopic surgery. Life-Cycle Assessments (LCAs) were included to quantify the climate impact. Exclusions included veterinary studies, general endoscopic procedures, and novel instruments. Conclusion: The search yielded 15 809 studies, 53 studies meeting the inclusion criteria: 38 compared disposable versus reusable instruments and 15 examined new versus reprocessed disposables. Reusables and/or reprocessed disposables showed favorable environmental and economic outcomes compared to new disposables. Instrument performance was comparable between the two groups. No studies were identified that investigated the clinical implications of contamination risk of disposables versus reusables. Six studies evaluating the contamination risk of reusables and reprocessed disposables showed residual pollution after cleaning and sterilization, although data on clinical outcome lacked. Interpretation: This review underscores the environmental benefits of reusables and favors both reusable and reprocessed disposables for their economic advantages. The lack of clear evidence favoring one type over the other in instrument performance necessitates further research. Addressing contamination risks requires additional studies on the clinical impact of residual substances. Future research should report outcomes on environmental sustainability, costs, instrument performance, and contamination risk.
Normal Gut Microbiomes in Diverse Populations: Clinical Implications
Authors: Omprakash Shete, Tarini Shankar Ghosh
Journal: Annual Review of Medicine (2024)

The human microbiome is a sensor and modulator of physiology and homeostasis. Remarkable tractability underpins the promise of therapeutic manipulation of the microbiome. However, the definition of a normal or healthy microbiome has been elusive. This is in part due to the underrepresentation of minority groups and major global regions in microbiome studies to date. We review studies of the microbiome in different populations and highlight a commonality among health-associated microbiome signatures along with major drivers of variation. We also provide an overview of microbiome-associated therapeutic interventions for some widespread, widely studied diseases. We discuss sources of bias and the challenges associated with defining population-specific microbiome reference bases. We propose a roadmap for defining normal microbiome references that can be used for population-customized microbiome therapeutics and diagnostics.
Position paper on the physiology and nomenclature of dual circulation during venoarterial ECMO in adults
Authors: Jenelle Badulak, Darryl Abrams, Andrew M. Luks, Bishoy Zakhary, Steven A. Conrad, Robert Bartlett, Graeme MacLaren, Leen Vercaemst, Roberto Lorusso, Lars Mikael Broman, Cara Agerstrand, Susanna Price, Alain Combes, Giles Peek, Eddy Fan, Kiran Shekar, John Fraser, Daniel Brodie
Journal: Intensive Care Medicine (2024)

When native blood flow through the aorta from the adult heart and lungs meets retrograde blood flow from an artificial heart and lung during venoarterial extracorporeal membrane oxygenation (VA-ECMO), the result is the creation of two separate circulations on either side of the blood flow mixing point. This phenomenon is known as dual circulation and is characterized by different content of oxygen and carbon dioxide between the circulations. There is currently a lack of clarity surrounding the nomenclature to describe this physiologic phenomenon in VA-ECMO and thus we endeavor to name and define these terms to facilitate clear communication and proper clinical management of these patients.
Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Authors: Mohammad Abdel Jawad, John A. Spertus, Uchechukwu Ikeaba, Stephen J. Greene, Gregg C. Fonarow, Karen Chiswell, Paul S. Chan
Journal: JAMA Cardiology (2024)

Importance Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) in August 2021 is unknown. Objective To examine trends and hospital-level variation in SGLT2i adoption. Design, Setting, and Participants This cohort study included patients with LVEF greater than 40% who were hospitalized for decompensated HF at 1 of 557 sites in the US between July 1, 2021, and September 30, 2023, from the Get With The Guidelines–Heart Failure registry. Main Outcomes and Measures Patient-level trends and site-level variation in prescription rates of SGLT2i at hospital discharge. Site-level variation was quantified using the median odds ratio, which describes the average odds that a patient being treated at one vs another randomly selected hospital would receive SGLT2i therapy at discharge. Results Of 158 849 patients (median [IQR] age, 76 [66-85] years; 89 816 females [56.5%]), 22 126 eligible patients (13.9%) with HF and an LVEF greater than 40% were prescribed an SGLT2i at hospital discharge. Quarterly prescription rates increased from 4.2% in July to September 2021 to 23.5% in July to September 2023 ( P for trend &amp;amp;lt; .001). SGLT2i prescription was more likely among patients with HF with mildly reduced LVEF (41%-49%) than in those with preserved LVEF (≥50%; 5127 of 27 712 patients [18.5%] vs 16 999 of 131 137 patients [13.0%]; absolute standardized difference, 16.7%). After adjustment for patient characteristics, there was a high variance between hospitals in the rate of SGLT2i prescription (median odds ratio, 2.12; 95% CI, 2.02-2.25). Among 518 hospitals with 10 or more eligible discharges, 11 hospitals (2.1%) discharged 50% or more of their patients with an SGLT2i prescription, while 232 (44.8%) discharged fewer than 10% of eligible patients with an SGLT2i prescription. Conclusion and Relevance For patients with HF and an LVEF greater than 40%, discharge prescription of SGLT2is increased from 4.2% to 23.5% during the first 2 years after the EMPEROR-Preserved trial demonstrating treatment benefits; however, these rates varied across US hospitals.
Exosome autoantibody biomarkers for detection of lung cancer
Authors: Win Lwin Thuya, Janique Michelle Peyper, Tan Ti Myen, Nur Diana Anuar, Arif Anwar, Ranga Gudimella, Nurul Huda Rutt, Nurul Shielawati Mohamed Rosli, Noorul Hidayah Badri, Teh Norleila Abdul Rahman, Raja Nurashirin, Gautam Sethi, John Kit Chung Tam, Andrea Li-Ann Wong, Ross Soo, Jonathan M. Blackburn, Lingzhi Wang, Boon Cher Goh
Journal: Military Medical Research (2024)
Adoptive transfer of membrane-restricted IL-12-TCR T cells promotes antigen spreading and elimination of antigen-negative tumor variants
Authors: Ling Zhang, Scott M Norberg, Farrah Karimipour, John S Davies, Alex Kuznetsov, Wiem Lassoued, Daniel Burnett, Philip Homan, Margaret Cam, Andrew Sinkoe, Ping Xue, James L Gulley, Christian S Hinrichs
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background Adoptive T-cell therapy has demonstrated clinical activity in B-cell malignancies, offering hope for its application to a broad spectrum of cancers. However, a significant portion of patients with solid tumors experience primary or secondary resistance to this treatment modality. Target antigen loss resulting either from non-uniform antigen expression or defects in antigen processing and presentation machinery is one well-characterized resistance mechanism. Constitutively expressed membrane-anchored interleukin-12 (caIL-12) has demonstrated enhanced antitumor activity and low systemic exposure in multiple preclinical adoptive T-cell treatment models with homogeneous tumor antigen expression. In this study, we assess the therapeutic impact of caIL-12 on target antigen-negative variants in syngeneic mouse models. Methods Target antigen-positive tumors were generated by transducing B16F10 melanoma cells (B16) or Lewis Lung Carcinoma cells (LLC) with a construct expressing the OVA antigen, SIINFEKL, tagged to ubiquitin (B16-U-OVA, LLC-U-OVA), while B16 or LLC tumors served as antigen-negative variants. C57BL/6J mice were subcutaneously injected with heterogeneous tumors composed of 80% B16-U-OVA and 20% B16. Bilateral tumors were established by injecting the left flank with B16-U-OVA or LLC-U-OVA tumors and the right flank injected with B16 or LLC tumors. The tumor-bearing mice then underwent 5.5 Gy total body irradiation, followed by adoptive transfer of OT-I TCR-T cells engineered with or without caIL-12. Results TCR-T cells (OT-I) delivered caIL-12 to the B16-U-OVA tumor sites and induced robust tumor control and survival benefits in mice bearing a heterogeneous tumor with OVA-negative variants. caIL-12 exerted its effect on OVA-negative B16 variants primarily by priming and activating endogenous antitumor CD8 T cells via antigen spreading. In addition, antigen spreading induced by OT-I-caIL-12 resulted in controlling OVA-negative tumors implanted at distant sites. This therapeutic effect required antigen-specific TCR-T cells and caIL-12 to colocalize at the tumor site, along with endogenous CD8 T cells capable of recognizing shared tumor antigens. Conclusion Expression of caIL-12 by tumor-targeting T cells demonstrated therapeutic effect against target-antigen-negative tumor variants, primarily through the induction of antigen spreading. These findings highlight the potential of caIL-12 to address challenges of antigen escape and tumor heterogeneity that may limit the efficacy of T-cell therapy against solid tumors.
Associations of Clinical Characteristics With Sudden Cardiac Arrest in People With Type 2 Diabetes With and Without Cardiovascular Disease: A Longitudinal Case-Control Study Using Routine Primary Care Data
Authors: Peter P. Harms, Laura H. van Dongen, Frank Bennis, Karin M.A. Swart, Mark Hoogendoorn, Joline W.J. Beulens, Hanno L. Tan, Petra P.J.M. Elders, Marieke T. Blom
Journal: Diabetes Care (2024)

OBJECTIVE To assess longitudinal associations with sudden cardiac arrest (SCA) of clinical characteristics recorded in primary care in people with type 2 diabetes (T2D), both with and without cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS We performed a case-control study, with SCA case subjects with T2D from the Amsterdam Resuscitation Studies (ARREST) registry of out-of-hospital resuscitation attempts in the Dutch Noord-Holland region (2010–2020) and up to five matched (age, sex, T2D, general practitioner [GP] practice) non-SCA control subjects. We collected relevant clinical measurements, medication use, and medical history from GPs’ electronic health care records. We analyzed the associations of clinical characteristics and medication use with SCA in the total sample and in subgroups with or without CVD using multivariable time-dependent Cox regression (hazard ratios, 95% confidence intervals). RESULTS We included 689 SCA case subjects and 3,230 non-SCA control subjects. In multivariable models, low fasting glucose (&amp;lt;4.5 mmol/mol: 1.91 [1.00–3.64]), antihypertensive (1.80 [1.39–2.33]), glucose lowering (oral only: 1.32 [1.06–1.63]; insulin only: 2.31 [1.71–3.12]; oral and insulin: 1.64 [1.21–2.22]), heart failure (1.91 [1.55–2.35]), and QTc-prolonging prokinetic (1.78 [1.27–2.50]), antibiotic (1.35 [1.05–1.73]), and antipsychotic (2.10 [1.42–3.09]) medication were associated with SCA in the total sample. In subgroup effect modification analyses, QTc-prolonging antibiotic (1.82 [1.26–2.63]) and antipsychotic (3.10 [2.09–4.59]) medication use were associated with SCA only in those without CVD. CONCLUSIONS In people with T2D, low fasting glucose and QTc-prolonging prokinetic, antibiotic, or antipsychotic medication use and a history of heart failure are associated with SCA risk. Subgroup analyses indicate antibiotic and antipsychotic medication use increases SCA risk specifically in those without CVD.
Clinical Pharmacology of Cytokine Release Syndrome with T-cell Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Authors: Kendra K. Radtke, Brendan C. Bender, Zao Li, David C. Turner, Sumedha Roy, Anton Belousov, Chi-Chung Li
Journal: Clinical Cancer Research (2024)

Abstract Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention is crucial in T-BiSp development. Required hospitalization for 7 of the 9 approved T-BiSp and the need for clinical intervention in severe cases highlight the importance of mitigation strategies to reduce healthcare burden and improve patient outcome. In this review, we discuss the emerging evidence on CRS mitigation, management, and prediction. We cover different strategies for dose optimization, current and emerging (pre)treatment strategies, quantitative pharmacology tools employed during drug development, and biomarkers and predictive factors. Insights are gleaned on step-up dosing and formulation effects on CRS and CRS relationships with cytokine dynamics and drug levels gathered through review of T-BiSp licensing applications and emerging data from conferences and publications.
Meta-analysis of longitudinal comparison of transcatheter versus surgical aortic valve replacement in patients at low to intermediate surgical risk
Authors: Mushood Ahmed, Areeba Ahsan, Aimen Shafiq, Zain A. Nadeem, Fariha Arif, Eeshal Zulfiqar, Muhammad H. Kazmi, Rukesh Yadav, Hritvik Jain, Raheel Ahmed, Mahboob Alam, Farhan Shahid
Journal: International Journal of Surgery (2024)
Apixaban removal during emergency surgery for type a acute aortic dissection. a prospective cohort study
Authors: Henriette Røed-Undlien, Nina H. Schultz, Inger M. Husebråten, Birgit M. Wollmann, Rupali R. Akerkar, Espen Molden, Erik K. Amundsen, Johannes L. Bjørnstad
Journal: International Journal of Surgery (2024)
Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?
Authors: Fernando R. Giugni, Jarett D. Berry, Amit Khera, Amil M. Shah, James A. de Lemos
Journal: Circulation (2024)

Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these areas are already informed by risk-assessment, but limited by the use of crude assessment tools with marginal performance. Risk assessment in prevention and population health may be improved with the use of genetics, circulating biomarkers, and imaging, leading to outcome-specific risk-prediction and enhanced phenotyping. Personalized management matching therapy to risk profile can be then implemented for either individuals or groups, improving cost-effectiveness and risk-benefit. Here, we explore this precision-like approach, including available tools, potential applications, and future perspectives for cardiovascular prevention and population health management.
Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia
Authors: Junxiu Liu, Brandon K. Bellows, David R. Jacobs, Jessica G. Woo, Elaine M. Urbina, Pallavi P. Balte, Elizabeth C. Oelsner, Dhruv S. Kazi, David Siscovick, Norrina B. Allen, Jamal S. Rana, John T. Wilkins, Michael E. Hall, Lydia A. Bazzano, Trudy L. Burns, Stephen R. Daniels, Terence Dwyer, Markus Juonala, Olli T. Raitakari, Alan R. Sinaiko, Julia Steinberger, Alison J. Venn, Noora Kartiosuo, Terho Lehtimäki, Costan G. Magnussen, Jorma S.A. Viikari, Sarah D. de Ferranti, Andrew E. Moran, Yiyi Zhang
Journal: Circulation (2024)
Letter by Lucijanic and Krecak Regarding Article, “Clonal Hematopoiesis of Indeterminate Potential With Loss of <i>Tet2</i> Enhances Risk for Atrial Fibrillation Through <i>Nlrp3</i> Inflammasome Activation”
Authors: Marko Lucijanic, Ivan Krecak
Journal: Circulation (2024)
AS-0249 Prevalence, Overlap, and Risk for Liver Fibrosis of MASLD, CVD, and CKD Conditions in U.S. Adults, NHANES 2017-March 2020
Authors: Hongxia Gong, Chunge Zhang, Ting Fu, Fuqiang Kan, Ningning Ji, Zewen Yang
Journal: Journal of the American College of Cardiology (2024)
AS-0248 Favorable Short-Term Clinical Outcomes in Patients With Type 2 Myocardial Infarction Complicated With Acute Respiratory Failure
Authors: Ze Zhang, Lei Zhu, Su-Tao Hu, Yu-Kun Zhang, Tian-Shu Gu, Chao Jiang, Jing-Kun Zhang, Xue Wu, Xing Liu, Tong Liu, Kang-Yin Chen
Journal: Journal of the American College of Cardiology (2024)
AS-0239 A Prognostic Model for Predicting Major Adverse Cardiovascular Events in Patients With Coronary In-Stent Restenosis
Authors: Boning Zhou, Xin Zhang, Zijie Dang, Jian Shen, Yang Jiao, Henan Liu, Yongkang Su, Jian Wang, Xiaoling Hou, Zhenhong Fu
Journal: Journal of the American College of Cardiology (2024)
AS-0302 Safety and Efficacy of Statin-Based Acipimox Therapy in Patients With Acute Myocardial Infarction with Elevated Triglyceride Levels
Authors: Tianshu Gu, Junyu Liu, Yukun Zhang, Sutao Hu, Ze Zhang, Jiayi Ren, Wenbo Dai, Zhengkai Xue, Jingkun Zhang, Xue Wu, Seung Woon Rha, Tong Liu, Kangyin Chen
Journal: Journal of the American College of Cardiology (2024)
AS-0352 U-shaped Association Between Cumulative Exposure Levels of LDL-C and Non–HDL-C and All-Cause Mortality in the Chinese Middle-Aged and Elderly Population
Authors: Zhiwen Xiao, Zhongqiu Lin, Wenlong Xu, Chuling Li, Yifei Ruan, Yingxuan Li, Xingqiao Chen, Fengling He, Guojun Chen, Weijing Feng, Jianping Bin, Yanmei Chen
Journal: Journal of the American College of Cardiology (2024)
AS-0285 Association of Serum Potassium Time in Target Range With Cardiovascular Outcomes in HFpEF Patients
Authors: Wenlong Xu, Zhiwen Xiao, Yating Tang, Yingxuan Li, Xingqiao Chen, Fengling He, Haoxiang Huang, Chuling Li, Yu Liu, Jiajun Zhou, Yuegang Wang, Jianping Bin, Yanmei Chen
Journal: Journal of the American College of Cardiology (2024)
AS-0031 Mildly Decreased eGFR Modifies the Association Between Uric Acid and Risk of Kidney Function Decline: a 5-Year Population-Based Cohort Study
Authors: Zeya Li, Yu Zhao, Weihua Chen, Dongjie Du, Xianzhong Gu, Rongchong Huang
Journal: Journal of the American College of Cardiology (2024)
AS-0104 U-Shaped Association Between Ankle-Ankle Index and Coronary Artery Calcification Progression: The Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Jikai Song, Da Teng, Qingwen Huang, Lei Gong, Chunxiao Wang, Haibin Dong, Hua Wang, Lin Zhong, Jun Yang
Journal: Journal of the American College of Cardiology (2024)
AS-0326 Proteomic Biomarker Discovery and Machine Learning–Based Prediction of Acute Coronary Syndrome in Young Adults: A Multi-Marker Study
Authors: Tangzhiming Li, Qian Li, Fengchao Liang, Benhui Liang, Cong Xu, Jianlong Yan, Da Yin, Xin Sun
Journal: Journal of the American College of Cardiology (2024)
AS-0192 The Role of Remaining Distal Tears After Proximal Repair of Stanford Type B Aortic Dissection
Authors: Simeng Zhang, Caiyi Wei, Dongchen Shi, Fengbo Pei, Yongxue Zhang, Zaiping Jing, Jie Liu, Qingsheng Lu, Yi Shi
Journal: Journal of the American College of Cardiology (2024)
AS-0190 Risk Factors for Early Major Adverse Cardiovascular Events After Surgical Repair of Supravalvular Aortic Stenosis
Authors: Simeng Zhang, Caiyi Wei, Fengbo Pei, Lizhi Lv, Bo Peng, Jianming Xia, Jun Yan, Jie Liu, Qiang Wang, Yi Shi
Journal: Journal of the American College of Cardiology (2024)
AS-0281 Experimental Study on Left Heart Interventional Surgery Through Atrial Septum Puncture via the Patent Foramen Ovale Occluder With Preservation of the Puncture Area
Authors: Yanlin Su, Hao Chen, Ziqian He, Yiting Wei, Zihe Dang, Suyan Cao, Wenlin Lu, Shaoqing Cao, Chengjian Yang, Haibin Jiang
Journal: Journal of the American College of Cardiology (2024)
AS-0227 The Net Clinical Benefit of Fondaparinux vs LMWH in Chinese Non–ST-Segment Elevation Acute Coronary Syndrome Patients: The REFOCAS Nonrandomized Controlled Trial
Authors: Dandan Li, Xiaodan Tuo, Yani Yu, Genshan Ma, Chuanyu Gao, Wei Mao, Peng Qu, Limin Liu, Zhuo Shang, Xunli Yin, Guozhen Wang, Aifen Liu, Yundai Chen
Journal: Journal of the American College of Cardiology (2024)
AS-0319 Supramolecular Self-Assembled Nanoparticles for Targeted Therapy of Myocardial Infarction by Regulating Mitochondrial Dynamic System
Authors: Shen Jian, Yang Yinuo, Zhang Xin, Jiao Yang, Su Yongkang, Liu Henan, Zhou Boning, Dang Zijie, Wang Jian, Hou Xiaoling, Wu Yan, Wang Haimang, Hongyu Zhang, Fu Zhenhong
Journal: Journal of the American College of Cardiology (2024)
AS-0178 STAT3 Regulation of Cystathionine γ-Lyase Confers Promising Therapy of Anthracycline Cardiomyopathy to an Endogenous Hydrogen Sulfide Donor, S-Propargyl-Cysteine
Authors: Jian Wu, Zhijun Wang, Wei Guo, Yizhun Zhu
Journal: Journal of the American College of Cardiology (2024)
AS-0076 Overexpression of USP2 Regulates MFN2 Deubiquitination Through the USP2/MFN2 Axis to Alleviate Mitochondrial Dysfunction and Myocardial Hypertrophy Induced by Angiotensin II–Induced Calcium Overload
Authors: Daoyao Fu, Mengxuan Xiao, Yuan Sui, Wenjun Xiong
Journal: Journal of the American College of Cardiology (2024)
AS-0304 Exploring Immune Modulation in Acute myocardial infarction: Novel Key Regulatory Genes Identified and Validated Through Advanced Bioinformatic and Machine Learning Techniques
Authors: Wu Zhengfeng, Zhang Honghong, Zhao Haijing, Zhu Yue, Yuhan Ma, Liu Yuqi
Journal: Journal of the American College of Cardiology (2024)
AS-0041 Sex Associations and Computed Tomography-Derived Fractional Flow Reserve to Guide the Management of Patients with Stable Coronary Artery Disease: From the TARGET trial
Authors: Yipu Ding, Zinuan Liu, Ran Xin, Ziqiang Guo, Yundai Chen, Junjie Yang
Journal: Journal of the American College of Cardiology (2024)
AS-0074 A U-Shape Relationship Between Free Fatty Acid Level and Adverse Outcomes in Coronary Artery Disease Patients With Hypertension: The PRACTICE Study
Authors: Ting-Ting Wu, Ying Pan, Chang-Jiang Deng, Ying-Ying Zheng, Xiang Xie
Journal: Journal of the American College of Cardiology (2024)
AS-0164 Inhibition of Hypoxia Inducible Factor 2α Suppresses Vascular Smooth Muscle Cell Phenotype Switching and Hypertension via Targeting Nox4-Mediated Mitochondrial Oxidative Stress
Authors: Qi Zhang, Xinxin Zhu, Jinmeng Jia, Xia Wang, Yutao Ma, Nan Zhao, None YutongCui, Jinhao Liao, Sijia Guan, Jinlong He, Aijuan Qu
Journal: Journal of the American College of Cardiology (2024)